MINI FUTURE LONG - GILEAD SCIENCES | Delayed Deutsche Boerse AG 01:05:11 2024-06-17 pm EDT | ||
| 1.03 EUR | -3.74% |
|
| Current month | +12.63% | ||
| 1 month | -17.69% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-17 | 1.03 | -3.74% |
| 24-06-14 | 1.07 | +18.89% |
| 24-06-13 | 0.9 | -4.26% |
| 24-06-12 | 0.94 | -5.05% |
| 24-06-11 | 0.99 | -4.81% |
Delayed Quote Deutsche Boerse AG
Last update June 17, 2024 at 01:05 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PF3LQJ |
| ISIN | DE000PF3LQJ3 |
| Date issued | 2020-10-27 |
| Strike | 53.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.99 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.76 € |
|---|---|
| Lowest since issue | 0.64 € |
| Spread | 0.01 € |
| Spread % | 0.96% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.06
USD
Average target price
82.7
USD
Spread / Average Target
+27.11%
- Stock Market
- Certificates
- Certificat
